JP2008528696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528696A5 JP2008528696A5 JP2007554228A JP2007554228A JP2008528696A5 JP 2008528696 A5 JP2008528696 A5 JP 2008528696A5 JP 2007554228 A JP2007554228 A JP 2007554228A JP 2007554228 A JP2007554228 A JP 2007554228A JP 2008528696 A5 JP2008528696 A5 JP 2008528696A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- complex
- serine
- group
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- 150000003904 phospholipids Chemical class 0.000 claims 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 4
- 229960001153 serine Drugs 0.000 claims 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 229950006137 dexfosfoserine Drugs 0.000 claims 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229920002307 Dextran Polymers 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 150000002632 lipids Chemical group 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- -1 serine compound Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000000232 Lipid Bilayer Substances 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 150000003354 serine derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/049,134 US7351688B2 (en) | 2003-02-05 | 2005-02-02 | Compositions and methods for less immunogenic protein formulations |
| PCT/US2006/003779 WO2006084095A1 (en) | 2005-02-02 | 2006-02-02 | Compositions and methods for less immunogenic protein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528696A JP2008528696A (ja) | 2008-07-31 |
| JP2008528696A5 true JP2008528696A5 (https=) | 2009-04-02 |
Family
ID=36777576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554228A Pending JP2008528696A (ja) | 2005-02-02 | 2006-02-02 | 低免疫原性のタンパク質製剤のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7351688B2 (https=) |
| EP (1) | EP1858532A4 (https=) |
| JP (1) | JP2008528696A (https=) |
| AU (1) | AU2006210609A1 (https=) |
| CA (1) | CA2596280A1 (https=) |
| NZ (1) | NZ560327A (https=) |
| WO (1) | WO2006084095A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007235463B2 (en) * | 2006-03-30 | 2012-11-22 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| EP1988101A1 (en) * | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| WO2013070362A1 (en) | 2011-10-06 | 2013-05-16 | The Research Foundation Of State University Of New York | Compositions and methods for immune tolerance induction |
| US10617640B2 (en) * | 2009-07-07 | 2020-04-14 | The Research Foundation For The State University Of New York | Phosphoserine containing compositions for immune tolerance induction |
| EP2451485B1 (en) * | 2009-07-07 | 2016-03-02 | The Research Foundation Of State University Of New York | Lipidic compositions for induction of immune tolerance |
| US8951563B2 (en) * | 2009-08-06 | 2015-02-10 | Technion Research & Development Foundation Limited | Antibiotic drug delivery and potentiation |
| CN107190034A (zh) | 2010-10-05 | 2017-09-22 | 诺沃—诺迪斯克保健股份有限公司 | 生产蛋白质的方法 |
| EP2704688B1 (en) * | 2011-05-05 | 2019-07-10 | Matinas BioPharma Nanotechnologies, Inc. | Cochleate compositions and methods of making and using same |
| EP3049103B1 (en) * | 2013-09-24 | 2020-06-24 | The Research Foundation for the State University of New York | Compositions and methods for reducing antigen-specific immunogenicity |
| EP3439636B1 (en) * | 2016-04-05 | 2023-06-07 | The Research Foundation for the State University of New York | Phosphoserine containing compositions for immune tolerance induction |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127502A (en) | 1977-06-10 | 1978-11-28 | Eastman Kodak Company | Stabilizers for reconstituted, lyophilized samples |
| US4795806A (en) | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| SE513221C2 (sv) * | 1998-04-17 | 2000-07-31 | Net Insight Ab | Förfarande och anordning för allokering av tidluckor till en kanal i ett kretskopplat tidsmultiplexerat nät |
| JP4545928B2 (ja) * | 1998-04-27 | 2010-09-15 | ジリップ・ファーマ・ビー．ブイ． | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 |
| US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| WO2003013245A1 (en) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| US20040229793A1 (en) | 2003-02-05 | 2004-11-18 | Balasubramanian Sathyamangalam V. | Compositions and methods for less immunogenic protein formulations |
-
2005
- 2005-02-02 US US11/049,134 patent/US7351688B2/en not_active Expired - Lifetime
-
2006
- 2006-02-02 AU AU2006210609A patent/AU2006210609A1/en not_active Abandoned
- 2006-02-02 JP JP2007554228A patent/JP2008528696A/ja active Pending
- 2006-02-02 CA CA002596280A patent/CA2596280A1/en not_active Abandoned
- 2006-02-02 EP EP06720199A patent/EP1858532A4/en not_active Withdrawn
- 2006-02-02 WO PCT/US2006/003779 patent/WO2006084095A1/en not_active Ceased
- 2006-02-02 NZ NZ560327A patent/NZ560327A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519383A5 (https=) | ||
| JP2004529163A5 (https=) | ||
| JP2018184470A5 (https=) | ||
| KR100381449B1 (ko) | 에테르지질리포좀과이들의제약학적용도 | |
| Dass et al. | Apolipoprotein A‐I, cyclodextrins and liposomes as potential drugs for the reversal of atherosclerosis. A review | |
| JP2015515992A5 (https=) | ||
| Rakotomanga et al. | Hexadecylphosphocholine interaction with lipid monolayers | |
| JP2008528696A5 (https=) | ||
| JP2019023243A5 (https=) | ||
| JP2016505545A5 (https=) | ||
| NL8002097A (nl) | Parenteraal toedienbare stabiele geneesmiddel- oplossingen. | |
| HRP20201761T1 (hr) | Prilagođeni liposomi za tretman bakterijskih infekcija | |
| US8252836B2 (en) | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease | |
| ATE469660T1 (de) | Gasgefüllte mikrovesikel mit polymer- modifizierten lipiden | |
| Dynarowicz-Latka et al. | Advantages of the classical thermodynamic analysis of single—and multi-component Langmuir monolayers from molecules of biomedical importance—theory and applications | |
| JP2010505937A5 (https=) | ||
| Das et al. | The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery | |
| JP5735724B2 (ja) | 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 | |
| JP2005505521A5 (https=) | ||
| CA2473395A1 (en) | Phospholipid bodies and use thereof in medical treatment | |
| JP2008519064A5 (https=) | ||
| FI3954360T3 (fi) | Hiilihydraattien lääkevalmiste terapeuttiseen käyttöön | |
| JP2008528696A (ja) | 低免疫原性のタンパク質製剤のための組成物および方法 | |
| EP0553272B1 (en) | Synthetic lung surfactant | |
| US20150125407A1 (en) | Vesicular Formulations, Uses and Methods |